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Serum chromogranin A is the most useful general and prognostic tumour marker available for neuroendocrine tumour (NET)
patients. The role of other tumour markers is less clear. In order to determine the diagnostic and prognostic value of serum a-
fetoprotein (AFP) and human chorionic gonadotrophin-b (hCGb) in NETs, a database containing biochemical, histological, and
survival data on 360 NET patients was constructed. This data was statistically assessed, using Statistical Package for the Social Sciences,
to determine the utility of commonly measured tumour markers with particular emphasis on AFP and hCGb. a-Fetoprotein and
hCGb were raised in 9.5 and 12.3% of patients respectively and jointly raised in 9.1% of patients in whom it was measured. a-
Fetoprotein levels associated strongly and positively with tumour grade, serum CgA and hCGb levels, and worse survival. Human
chorionic gonadotrophin-b levels also associated strongly and positively with serum CgA and AFP levels, and worsening survival. a-
Fetoprotein and hCGb are elevated in high-grade NETs, with a rapidly progressive course and poorer survival. They also correlate
with chromogranin-A, which is known to be a marker of tumour burden and to have prognostic value. Thus AFP and hCGb are
clinically important in NETs and when elevated are poor prognostic markers.
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Neuroendocrine tumours (NETs) comprise a heterogeneous group
of tumours classified as being either functional, with symptoms
due to hormone secretion, or nonfunctional due to an apparent
lack of hormone-associated symptoms (Solcia et al, 2000). The
functional tumours may produce specific hormones, the measure-
ment of which can aid diagnosis and management; for example,
serotonin with midgut carcinoid tumours, insulin with insulinoma,
and gastrin in gastrinoma. Currently, the most useful ‘general’ NET
marker is plasma CgA, and recent guidelines are recommending
that all patients with NETs should have their CgA measured
(Ramage et al, 2005; Rindi et al, 2006a).
Tumour markers can provide valuable information on tumour
functionality and presumed tumour burden in relation to
antitumour therapy. For example, an indolent nonfunctioning
NET may produce increased amounts of CgA as the first sign of a
switch to a more progressive course. Alternatively, antitumour
therapy may not display tumour response as determined
radiologically, using the RECIST criteria, as tumour cells may be
replaced by fibrosis with a resultant lack of change in overall
tumour size. However, there may be a significant decline in the
level of circulating tumour markers together with significant
symptomatic improvement. In addition, tumour markers can have
prognostic value: plasma neurokinin-A has been shown to be an
accurate marker of prognosis in midgut NETs, with rising
neurokinin-A levels despite somatostatin analogue therapy shown
to be associated with poorer prognosis (Turner et al, 2006);
patients with CgA greater than 5000mgl
 1 have a 5-year survival of
only 22% as opposed to 63% for patients with serum chromo-
granin-A levels of less than 5000mgl
 1 (Janson et al, 1997).
Absolute plasma CgA levels may also help to differentiate between
localised and diffuse NET spread, as well as between chronic active
gastritis and NETs (Campana et al, 2007).
There is a continuing need for tumour markers that can provide
further diagnostic and prognostic information in NET patients. a-
Fetoprotein (AFP) and human chorionic gonadotrophin-b (hCGb)
have previously been reported as being elevated in some NET
patients; however, the utility of these markers in NET patients has
not been determined (Ramage et al, 2005). Lokich et al (1987)
reported, in a small series, that AFP may be raised in a small
proportion of NET patients and that it may provide some useful
information. However, this initial report has not been further
explored. a-Fetoprotein is reactivated in numerous cancers,
including hepatocellular carcinoma and teratocarcinomas. The
basis of this reactivation is not well understood, but may involve
changes in the level or activity of transcriptional regulators (Spear,
1999).
Human chorionic gonadotrophin-b belongs to the glycoprotein
hormone family that also comprises luteinising hormone (LH),
follicle-stimulating hormone, and thyroid-stimulating hormone.
All members are heterodimers consisting of an a- and a b-subunit.
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sThe a-subunit, which is common to all glycoprotein hormones,
contains 92 amino acids. The b-chains determine the biological
activity and display extensive homology, with that between hCGb
and LHb being about 80%. Human chorionic gonadotropin is
mainly used for detection and monitoring of pregnancy
and pregnancy-related disorders, and as an extremely sensitive
and specific marker for trophoblastic tumours of placental and
germ cell origin (Stenman et al, 2006).
The aims of this study were to determine the role of AFP and
hCGb as diagnostic and prognostic markers, their relationship
with other tumour markers, as well as their value in predicting
disease progression in NET patients.
PATIENTS AND METHODS
We have developed a database of NET patients, containing
biochemical, radiological, histological, and survival data available
for 360 patients. Patients had been consented for approval of
utilisation of blood and tissue results for research purposes.
Pretreatment biochemical data included tumour markers AFP,
hCGb, and CgA. Histology data were collected to determine
tumour grade. Neuroendocrine tumour histological grading was
assessed according to the new TNM classification, including
differentiation of tumour and proliferation index Ki-67 (MIB-1):
thus classified as low-grade (G1) mitotic count o2/10 high-
powered fields (HPF) or Ki-67 p2%; intermediate-grade (G2)
mitotic count 2–20/10 HPF or Ki-67 3–20%; and high-grade
(G3) mitotic count 420/10 HPF or Ki-67 420% (Rindi et al,
2006b). Of the 360 patients in the database, 294 had been tested for
AFP. Of these, 294 patients, a subset of 28 patients, was identified
with serum AFP levels at least 1.5 the upper limit of normal. A
further 40 patients with normal AFP were randomly chosen from
the database to act as an age- and sex-matched control for the
AFP-high patients. In all, 268 patients had been tested for hCGb,o f
which 33 patients had hCGb levels at least 1.5 the upper limit of
normal. A further 33 patients with normal hCGb were randomly
chosen from the database to act as an age- and sex-matched
control for the hCGb-high patients.
A subset of 21 patients was derived from the AFP and hCGb
groups that had raised AFP and hCGb in combination. This subset
comprised 9.1% of patients in whom the two markers had been
measured. Control group had normal serum AFP and hCGb levels.
Statistical Package for the Social Sciences was utilised to
determine any difference between the two tumour marker groups
and their respective controls (Mann–Whitney U-test for nonpara-
metric samples; Tables 1, 3 and 5); to discover any correlations
between the parameters recorded (Spearman’s r; Tables 2, 4 and
6); and to look for survival differences (Kaplan–Meier survival
curves; Figures 1–3).
RESULTS
AFP group
Twenty-eight out of 294 patients (9.5%) had elevated AFP.
The AFP-high and control groups were compared using
Mann–Whitney U-test, for two nonparametric samples, to look
for significant differences in age and gender makeup of the two
groups. This confirmed the two groups to be evenly matched for
age and sex (Table 1). There were significant differences between
Table 1 Comparison of demographic and tumour marker data for the raised-AFP and control groups demonstrating the two groups to be evenly
matched for age, gender, and diagnosis
High AFP Control P-value (Mann–Whitney U-test)
Age at diagnosis 51 48 0.597
Sex (M/F) 15/13 18/22 0.495
Diagnosis
Metastatic NET (of unknown primary) 9 13
Pancreatic NET 11 16
Gastrinoma 1 2
Bronchial 2 4
Midgut NET 1 3
Hindgut NET 1 0
MTC 1 1
Thymic NET 1 1
Pelvic NET 1 0
Mean AFP (0–11.3ngml
 1) 273.8 3.5 0.001
Mean hCGb (o2.5mIUml
 1) 21.3 1.6 0.001
Mean CgA (0–60Ul
 1) 423 113 0.002
Mean Ki-67 (MIB-1) 21 10 0.009
Mean survival (months) 37.6 69 0.001
Stage IV disease (WHO classification) 24 of 28 (86%) 25 of 40 (63%) 0.037
AFP¼a-fetoprotein; hCGb¼human chorionic gonadotrophin-b ;N E T ¼neuroendocrine tumour. Significant differences between the two groups are apparent for the
expression of tumour markers AFP, hCGb, CgA, Ki-67 score, and survival from the time of diagnosis.
Table 2 Correlation of AFP levels with Ki-67 score, serum hCGb, and CgA levels, as well as survival in NET patient
Ki-67 (MIB-1) hCGb CgA Survival in months
Spearman’s r AFP Correlation coefficient 0.381 (**) 0.558 (**) 0.451 (**)  0.419 (**)
Significant (two-tailed) 0.007 0.000 0.000 0.001
AFP¼a-fetoprotein; hCGb¼human chorionic gonadotrophin-b ;N E T¼neuroendocrine tumour. **Correlation is significant at the 0.01 level (two-tailed).
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sthe two groups for the measured tumour markers AFP, hCGb,
CgA, MIB-1 (Table 1), and survival as measured from the time of
diagnosis (Figure 1; Table 1).
The data from the two groups were then combined for further
statistical analysis to determine possible correlations between the
five parameters studied: absolute levels of AFP, MIB-1, hCGb, CgA
and patient survival. Spearman’s r test was applied to the data
(Table 2). Serum AFP levels were discovered to correlate with the
four parameters measured. Thus, rising serum AFP levels strongly
and positively correlated with rising hCGb and CgA levels, and
MIB-1 scores. There was an additional strongly negative correla-
tion with survival from the time of diagnosis (significant at the 0.01
level) (Table 2).
Human chorionic gonadotrophin-b group
Thirty-three out of 268 patients (12.3%) had elevated hCGb. The
hCGb-high and control groups were compared using Mann–
Whitney U-test, for two nonparametric samples, to look for
significant differences in age and gender makeup of the two
groups. This confirmed the two groups to be evenly matched for
age and sex (Table 3). There were significant differences between
the two groups for the measured levels of tumour markers hCGb,
AFP, CgA, and survival as measured from the time of diagnosis
(Table 3; Figure 2), but not for MIB-1 scores (Table 3).
The data from the two groups were then combined for further
statistical analysis to determine possible correlations between the
five parameters studied: absolute levels of hCGb, AFP, MIB-1, CgA,
and survival from time of diagnosis. Spearman’s r test was applied
to the data (Table 4).
Serum hCGb levels were discovered to be correlated with three
of four other parameters measured. That is, rising serum hCGb
levels strongly and positively correlated with rising AFP and CgA
levels. Rising hCGb levels negatively correlated with survival from
the time of diagnosis (significant at the 0.01 level) (Table 4). No
correlation was found between hCGb levels and MIB-1 score.
Combined AFP/hCGb group
Twenty-one out of 230 patients (9.1%) had combined elevation of
serum AFP and hCGb. The combined AFP/hCGb-high and control
groups were compared using Mann–Whitney U-test, for two
nonparametric samples, to look for significant differences in age
and gender makeup of the two groups. This confirmed the two
groups to be evenly matched for age and sex (Table 5). There were
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Figure 1 Kaplan–Meier graph comparison of 5-year survival between
the high-AFP and control (normal-AFP) groups (P¼0.001).
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Figure 2 Kaplan–Meier graph comparison of 5-year survival between
the high-hCGb and control (normal-hCGb) groups (P¼0.037).
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Figure 3 Kaplan–Meier graph comparison of 5-year survival between
the combined high-AFP/hCGb and control (normal-AFP/hCGb) groups
(P¼0.001).
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levels of tumour markers hCGb, AFP, CgA, and survival as
measured from the time of diagnosis (Table 5; Figure 3), but not
for MIB-1 scores (Table 5).
The data from the two groups were then combined for further
statistical analysis to determine possible correlations between the
five parameters studied: absolute levels of hCGb, AFP, MIB-1, CgA,
and survival from time of diagnosis. Spearman’s r test was applied
to the data (Table 6).
These statistical tests discovered the serum AFP levels to
correlate with the four parameters measured. That is, rising serum
AFP levels strongly and positively correlated with rising hCGb and
CgA levels, and MIB-1 scores; rising serum AFP strongly and
negatively correlated with survival from the time of diagnosis
(significant at the 0.01 level) (Table 6). Serum hCGb levels
correlated with three of four other parameters measured. That is,
rising serum hCGb levels strongly and positively correlated with
rising AFP and CgA levels. Rising hCGb levels negatively
correlated with survival from the time of diagnosis (significant at
the 0.01 level) (Table 6). No correlation was found between hCGb
levels and MIB-1 score (Table 6).
DISCUSSION
A number of putative tumour markers are measured in NET
patients, with CgA having the highest expression in NETs and
being considered the most useful diagnostic and prognostic
marker (Janson et al, 1997; Turner et al, 2006; Campana et al,
2007). Tumour markers are measured at regular intervals and may
be useful for monitoring disease progression. Often a rise in
tumour marker levels may precede clinical indicators of disease
progression such as worsening diarrhoea, facial flushing, and
weight loss, as well as objective indicators of disease progression as
determined radiologically. Furthermore, an increase in the number
of expressed tumour markers is associated with worsening
prognosis (Ardill and Erikkson, 2003).
To date, there is only limited data on most tumour markers
measured in NET patients, which has thus created uncertainty
about their role. Clinical impression of a linkage between high-
grade aggressive tumours and a rise in serum AFP and hCGb levels
led us to perform a systematic review of the utility of AFP and
hCGb measurement in our NET patients. Although, very little is
known about AFP in NETs, some useful data already exist on the
expression and value of a- and b-subunits of hCG (Heitz et al,
1987; Eriksson et al, 1989; Grossmann et al, 1994; Nobels et al,
1997). These subunits have been shown to be raised in a significant
proportion of NET patients and to have the ability to differentiate
between benign and malignant gastroenteropancreatic tumours
(Heitz et al, 1987; Eriksson et al, 1989; Grossmann et al, 1994).
However, neither AFP nor subunits of hCG are able to differentiate
between NETs and other tumours (Nobels et al, 1997; Yuen and
Lai, 2005).
This analysis of a large NET patient database demonstrates, for
the first time, the ability of two easily measurable agents to
prognosticate in NET patients. Both AFP and hCGb are shown to
be related to poorer survival, with the clearest difference being
seen between the group of patients with combined rise in AFP and
hCGb in comparison to controls matched for age at diagnosis and
sex. However, only AFP associated with Ki-67. This can be
explained by the fact that there are significant differences in the
disease stage between the AFP-high group and its control group,
whereas no significant differences in the disease stage existed
between the hCGb-high group and its control group (Tables 1 and 3).
Table 3 Comparison of demographic and tumour marker data for the raised-hCGb and control groups demonstrating the two groups to be evenly
matched for age, gender, and diagnosis
High hCGb Control P-value (Mann–Whitney U -test)
Age at diagnosis 55 54 0.891
Sex (M/F) 16/17 16/17
Diagnosis
Metastatic NET (of unknown primary) 8 7
Pancreatic NET 15 11
Gastrinoma 2 1
Bronchial 4 5
Midgut NET 1 6
Hindgut NET 1 1
MTC 1 1
Thymic NET 1 1
Mean hCGb (o2.5mIUml
 1) 198.7 2.0 0.001
Mean AFP (0–11.3ngml
 1) 238.1 7.9 0.001
Mean CgA (0–60Ul
 1) 414.2 180.3 0.02
Mean Ki-67 (MIB-1) 13 14 0.63
Mean survival (months) 48 57.3 0.037
Stage IV disease (WHO classification) 27 of 33 (82%) 24 of 33 (73%) 0.382
AFP¼a-fetoprotein; hCGb¼human chorionic gonadotrophin-b ;N E T ¼neuroendocrine tumour. Significant differences between the two groups are apparent for the
expression of tumour markers AFP, hCGb, CgA, and survival from the time of diagnosis.
Table 4 Correlation of hCGb levels with AFP and CgA levels
Ki-67 (MIB-1) AFP CgA Survival in months
Spearman’s r hCGb Correlation coefficient 0.012 0.634 (**) 0.291 (*)  0.229
Significant (two-tailed) 0.931 0.000 0.019 0.074
AFP¼a-fetoprotein; hCGb¼human chorionic gonadotrophin-b ;N E T¼neuroendocrine tumour. There is also a trend towards a statistically significant correlation between
hCGb levels and survival, but clear absence of linkage between hCGb levels and Ki-67 score. **Correlation is significant at the 0.01 level (two-tailed). *Correlation is significant at
the 0.05 level (two-tailed).
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sAlthough overall AFP is elevated only in a minority of NET
patient, this data analysis demonstrates the ability of AFP to
highlight a group of NET patients with aggressive, high-grade
tumours and poor prognosis. Interestingly, four patients with
raised AFP did not have liver metastases but did have large volume
disease elsewhere (neck, peritoneum, and chest). Thus AFP is
likely to be a marker of tumour cell de-differentiation rather than a
marker of hepatic metastases from NETs.
Human chorionic gonadotrophin-b also provides prognostic
information with its demonstrated correlation with impaired
survival and other markers of a poor outcome, namely CgA and
AFP. When hCGb is high, as defined by levels 41.5 upper limit of
normal, the Mann–Whitney U-test applied to these values
demonstrates a clear difference in survival between the two groups
(Table 3). On determining a correlation between the absolute hCGb
level and degree of impairment of survival, although there is a trend
to impaired survival this is not statistically significant (Table 4). The
results of these analyses demonstrate that an abnormally high hCGb
is more informative than the absolute level itself. Thus hCGb, when
raised, is a marker of poor prognosis (Table 3, Figure 2).
The clearest predictions, however, can be made for those
patients with a combined rise in both serum AFP and hCGb levels.
These are strongly associated with high CgA levels and worsening
prognosis. Conversely, patients with normal AFP and hCGb levels
have low serum CgA levels and an excellent 5-year prognosis
(Figure 3).
Most NET patients have extensive metastases at the time of
diagnosis. The indolent nature of these tumours means that even
in the presence of liver metastases, the 5-year survival rates are
surprisingly good. However, a proportion of patients have rapidly
progressive disease, at diagnosis, which requires aggressive
management with cytoreductive therapies, hopefully resulting in
better symptom control and improved survival. Predicting the
behaviour of NETs in individual cases has to date relied on tumour
histology, serum CgA levels, and serial radiology imaging. This
data clearly demonstrate the utility of AFP, hCGb, CgA, and
possibly Ki-67 index in highlighting those patients with WHO
stage IV disease who are going to require intensive monitoring and
possibly early and aggressive therapy. Conversely, patients with
favourable results can be re-assured about their medium- to long-
term survival and monitored less intensely with confidence,
perhaps six monthly as opposed to three to four monthly for
those patients with, for example, elevated AFP and hCGb.
This is a retrospective study and the results highlight the worth
of performing a prospective study to assess these markers.
In conclusion, this study has identified AFP and hCGb to be
capable of providing significant prognostic information relevant to
the management of NET patients.
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